DIRS.INFO The most relevant business & tech news

☆ Anne Hathaway showed Blake Lively just what to do to swerve public backlash
▼ + stars: | 2024-10-09 | by ( Mikhaila Friel | ) www.businessinsider.com time to read: +7 min

Anne Hathaway apologized to journalist Kjersti Flaa for being difficult in a 2012 interview. AdvertisementAnne Hathaway just gave a masterclass in swerving public backlash — and Blake Lively should take notes, according to PR experts. PR experts told BI that Hathaway's swift response will minimize potential backlash and strengthen her reputation as a relatable and genuine celebrity. Advertisement"A lot of people wouldn't give me roles because they were so concerned about how toxic my identity had become online," Hathaway told Vanity Fair back in March. Blake Lively could learn from Hathaway, experts sayHathaway's response to Flaa was a complete contrast to Blake Lively, who remained silent after her 2016 interview with the same journalist went viral in August.

Persons: Anne Hathaway, Kjersti Flaa, Flaa, Blake Lively, Lively, —, Lively —, Hathaway, Jake Holyoak, Anne, Cindy Ord, Yely, Kopan, Les Misérables, Dave M, Charly Triballeau, It's, Holyoad, Blake, Hathaway's, Zoe Mumba, Mumba, Colleen Hoover's Organizations: Service, Input Communications, Playbill, Forbes, Getty, Hollywood Reporter Locations: Flaa, AFP

Many influencers seek out talent managers to help them grow their brands and make more money. Business Insider is seeking nominations for rising stars in influencer talent management. download the app Email address Sign up By clicking “Sign Up”, you accept our Terms of Service and Privacy Policy . AdvertisementSome talent managers have recently come into the spotlight in the past few years, representing some of the most sought-after influencers or helping their clients execute particularly successful partnerships. BI is seeking nominations for this year's rising stars in talent management.

Persons: —, Brittany Bright Organizations: Business, Service, YouTube, Influencer League

☆ Photographer who accused Taylor Swift's father of assaulting him says he's never been 'punched in the chops, particularly by the talent's dad'
▼ + stars: | 2024-02-27 | by ( Eammon Jacobs | ) www.businessinsider.com time to read: +3 min

Photographer Ben McDonald accused Taylor Swift's dad of punching him in Sydney, Australia. He said he's never been "punched in the chops, particularly by the talent's dad." AdvertisementA photographer accused Taylor Swift's dad, Scott Swift, of punching him as he tried to take her photo in Australia in the early hours of Tuesday morning. "Police have been told a 71-year-old man allegedly assaulted a 51-year-old man at Neutral Bay Wharf about 2.30am before leaving the location," a New South Wales Police spokesperson told Business Insider. "In 23 years, I haven't been assaulted and punched in the chops, particularly by the talent's dad," McDonald told the Associated Press.

Persons: Ben McDonald, Taylor Swift's, McDonald, he's, —, Scott Swift, Taylor, haven't, didn't, Nicole Kidman, Nicole, Ben McDonald's Organizations: Service, Police, New South Wales Police, North Shore Police Area Command, Swift, Daily Mail Australia, Associated Press, Business Locations: Sydney, Australia, New, Australian

☆ Weight loss drugs are still hard to find — but Novo Nordisk and Eli Lilly are trying to change that
▼ + stars: | 2024-02-10 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +8 min

Victoria Klesty | ReutersThe insatiable demand for weight loss drugs is trouncing supply, leaving many patients struggling to find the injectable treatments. The dominant weight loss drugmakers, Novo Nordisk and Eli Lilly , have said supply woes likely won't go away anytime soon, as the popularity of those medicines continues to soar. Some Wall Street analysts project that the weight loss drug market could be worth $100 billion by the end of the decade. But both Novo Nordisk and Eli Lilly gave updates on positive supply developments to investors over the last week. Other forms of weight loss drugs could helpAlternative forms of weight loss drugs could also help alleviate supply constraints in the future.

Persons: Victoria Klesty, Eli Lilly, Cantor Fitzgerald, Louise Chen, Nordisk's Wegovy, Eli Lilly's Zepbound, Goldman Sachs, Jeff Friedman, Novo, Mike Segar, Eli, Catalent, Yves Herman Yves Herman, TD Cowen, Michael Nedelcovych, Anat Ashkenazi, Cantor Fitzgerald's Chen, Morgan Stanley, Eli Lilly's, George Frey Organizations: Novo Nordisk, CNBC, Nordisk's, University of Florida, Pfizer, AstraZeneca, Roche, Food, Nordisk, Company, FDA, Novo Holdings, Wegovy, REUTERS, Reuters, U.S Locations: Oslo, Norway, Novo, U.S, Branchburg , New Jersey, Brussels, Belgium, Catalent, Concord , North Carolina, North, Germany, Indiana, Denmark, France

Still, Eli Lilly and Novo Nordisk appear to be making some encouraging progress. Eli Lilly wasn't the only weight loss drug producer to see positive supply developments in the last week. Novo Holdings, which owns almost 77% of the voting shares in Novo Nordisk, said Monday it will acquire drug manufacturer Catalent in a $16.5 billion deal. Novo Nordisk will then buy three of Catalent's manufacturing plants from Novo Holdings for $11 billion. Tema in November launched an ETF whose key holdings include companies benefiting from the hype around weight loss drugs.

Persons: Eli Lilly, Anat Ashkenazi, Incretin, Eli Lilly's, Ashkenazi, Eli Lilly wasn't, Yuri Khodjamirian, Danish drugmaker Organizations: Novo Nordisk, Holdings, Wegovy, Novo Holdings, CNBC, Tema, Nordisk, Reuters Locations: North Carolina, Novo, Tema, Brussels, Danish, U.S

☆ Novo Nordisk parent to buy Catalent for $16.5 billion to expand Wegovy supply
▼ + stars: | 2024-02-05 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +2 min

Novo Nordisk will then buy three of Catalent's manufacturing sites from Novo Holdings for $11 billion. Novo Holdings owns almost 77% of the voting shares in Novo Nordisk. Novo Nordisk and Novo Holdings said they expect the acquisition of the plants and the broader deal to buy Catalent to close at the end of 2024. Novo Nordisk added that it expects its purchase to gradually help increase its filling capacity beginning in 2026. Under the terms of the deal, Novo Holdings will buy Catalent for $63.50 a share in cash, a premium of 16.5% to Catalent's closing price on Friday.

Persons: Catalent, Eli Lilly Organizations: Nordisk, Novo Holdings, Novo Nordisk's Wegovy, Novo Nordisk, Novo, Elliott Investment Management, U.S ., Reuters, CNBC PRO Locations: Novo, Italy, Belgium, Bloomington , Indiana, Denmark, France, U.S, Brussels

☆ Cramer's Lightning Round: 'Stay away' from Catalent
▼ + stars: | 2023-11-29 | by ( Julie Coleman | ) www.cnbc.com time to read: +1 min

Stock Chart Icon Stock chart icon Vishay Intertechnology's year-to-date stock performance. Stock Chart Icon Stock chart icon Abbott Laboratories' year-to-date stock performance. Stock Chart Icon Stock chart icon Anheuser-Busch's year-to-date stock performance. Stock Chart Icon Stock chart icon Catalent's year-to-date stock performance. Stock Chart Icon Stock chart icon Moelis & Company's year-to-date stock performance.

Persons: Vishay, you've, Lads, Jim Cramer's Organizations: Abbott Laboratories, Anheuser, Moelis Locations: Catalent

☆ Social and influencer-marketing agency The Fifth, part of Murdoch's News Corp, is shutting down its UK talent division
▼ + stars: | 2023-11-14 | by ( Marta Biino | ) www.businessinsider.com time to read: +3 min

The Fifth, a social-creative agency originating in the UK, is shutting down its talent-management arm in the country, the company confirmed to Business Insider. The company is part of News UK, a media conglomerate that operates news outlets like The Times, The Sunday Times, and The Sun. The Fifth was founded in 2019 by Oliver Lewis, formerly News UK's director of digital strategy and partnerships, and The Fifth's talent division was launched a year later. Citing changes in the UK market, the company said it had decided to focus its efforts on the social-creative and influencer-marketing side of the business. Do you work at The Fifth or other talent management firms in the UK or have insight to share?

Persons: Oliver Lewis, It's, Dan Wang Organizations: Business, News UK, Times, Sunday Times, Sun . News, Rupert Murdoch's News Corp, Eurostar, BareMinerals, Columbia Business School

☆ Does ambition die in Austin? These tech workers don't think so.
▼ + stars: | 2023-10-21 | by ( Jordan Pandy | ) www.businessinsider.com time to read: +7 min

AdvertisementAdvertisementAn aerial view of a Union Pacific train entering downtown on April 21, 2023 in Austin, Texas. "Now it seems like there's a ton of really, really impressive people," Entwistle told Insider in July. Austinites still feel connected to the tech scene, but aren't ruled by it. AdvertisementAdvertisement"One of the things that we were so grateful for is access to outdoor activities," she told Insider. "Austin was one of the last places towards the end of my time traveling around that I had visited," he told Insider.

Persons: —, Brandon Bell, Hailey Eustace, Evan Baehr, Austin, Alicia Teagle, Austin —, Teagle, it's, John Andrew Entwistle, John Andrew Entwistle John Andrew Entwistle, talent's, Entwistle, Eustace, Austinites, aren't, San Francisco who've, Austin wasn't oversold, White, Sarah Hollingsworth, Robert Johnson, Robert Johnson Robert Johnson Organizations: Service, Austin Chamber, Union Pacific, Health, Learn, Apple, Google, Austin, Austin —, Lone Star State Locations: Austin, San Francisco, New York, Texas, Austin ., Austin , Texas, Francisco, Germany, Miami, Savannah, New York City, San Antonio, Lake Austin

☆ Weight-loss drugs fuel boom for firms that fill syringes
▼ + stars: | 2023-10-09 | by ( Maggie Fick | ) www.reuters.com time to read: +6 min

[1/5] Catalent's automated visual inspection systems that check every pre-filled syringe to ensure product integrity are seen, in Brussels, Belgium, 2023. Eli Lilly's (LLY.N) Mounjaro is expected to be approved for weight-loss in the United States this year. The U.S. Inflation Reduction Act is also boosting development of biologic drugs, some of which are injected. Injectables are increasingly used in elderly care settings, and some new Alzheimer's and generic arthritis drugs are administered by injection. One healthcare investor said CDMOs' ability to boost capacity will determine how fast the obesity drug market grows.

Persons: Wegovy, it's, Savant, Morgan Stanley, Eli Lilly's, Mounjaro, Chris Chen, Cornell Stamoran, Fujifilm Diosynth, Germany's Vetter, Lilly, Marc Casper, CDMOs, Luke Sergott, Catalent, Catalent's Stamoran, Maggie Fick, Patrick Wingrove, Josephine Mason, Catherine Evans Organizations: REUTERS Acquire, Pfizer, HK, Fujifilm, Fujifilm Corp, Novo, Reuters, Research, Insight Partners, Barclays, Thomson Locations: Brussels, Belgium, Handout, United States, WuXi, Europe, GLP, Anagni, Italy, Bloomington , Indiana, U.S, New York

A general view of the drug product manufacturing laboratory in biologics and sterile injectables, Catalent, in Brussels, Belgium June 27, 2023. Catalent named three pharma industry executives and a senior Elliott executive to its board and said John Greisch, who has served on the board since 2018, will become executive chairman. Elliott, whose stake in Catalent became public last month, has been engaging with the company behind the scenes for months. Two of the directors were picked by Elliott, while two were mutually agreed by Elliott and Catalent. Catalent is also forming a new strategic and operational review committee which Greisch will chair.

Persons: Yves Herman, Elliott, Catalent, Alessandro Maselli, John Greisch, Max, William Blair, Maselli, Steven Barg, Goldman Sachs, Frank D'Amelio, Stephanie Okey, Michelle Ryan, Greisch, Merck KGaA, Svea Herbst, Bayliss, Maggie Fick, Sriparna Roy, Shinjini Ganguli, Catherine Evans, Mike Harrison Organizations: REUTERS, Catalent Inc, Elliott Investment Management, Reuters, Novo, pharma, U.S . Food, Drug Administration, Pfizer, Johnson, Catalent, Svea, Thomson Locations: Brussels, Belgium, ., Danish, Novo, United States, Catalent, GLP, Boston, London, Bengaluru

A general view of the drug product manufacturing laboratory in biologics and sterile injectables, Catalent, in Brussels, Belgium June 27, 2023. The sources declined to be identified because the information is confidential and cautioned a deal could still collapse at the last minute. Spokespeople for Catalent and Elliott declined to comment. In the past when Elliott has pushed for sales of pieces or the entire target company, including at eBay and Switch Inc., and then won board representation, significant ownership changes have followed. Novo Nordisk's weight-loss drug Wegovy is filled by Catalent’s Brussels factory and last week Reuters reported that Catalent’s plant in Bloomington, Indiana will begin filling Wegovy injection pens for Novo.

Persons: Yves Herman Acquire, Elliott, Catalent, Elliott isn't, Keith Meister's, Scott Ferguson's, Mauricio Gutierrez, Svea Herbst, Bayliss, Maggie Fick, Shri Navaratnam Organizations: REUTERS, Catalent, Elliott Investment Management, AstraZeneca, Johnson, Moderna, eBay, Inc, Deutsche Bank, Management, Capital Management, Reuters, NRG, Svea, Thomson Locations: Brussels, Belgium, U.S, Bloomington , Indiana, Novo, Boston, London

A general view of the drug product manufacturing laboratory in biologics and sterile injectables, Catalent, in Brussels, Belgium June 27, 2023. Spokespeople for Catalent and Elliott declined to comment. The U.S.-based contract drugmaker is also Danish company Novo Nordisk's (NOVOb.CO) main manufacturing partner for its popular weight-loss drug Wegovy. The volatility at Catalent could increase scrutiny on the relationship between Novo and its partner. Reuters reported last week that a second Catalent factory will begin filling Wegovy injection pens for Novo as part of an expanded supply agreement.

Persons: Yves Herman Acquire, Elliott, drugmaker, Markus Manns, Catalent, Elliott isn't, Keith Meister's, Scott Ferguson's, Mauricio Gutierrez, Svea Herbst, Bayliss, Maggie Fick, Amanda Cooper, Shri Navaratnam, Bernadette Baum, Catherine Evans Organizations: REUTERS, Elliott Investment Management, Catalent, Novo, Reuters, Union Investment, AstraZeneca, Johnson, Moderna, eBay, Inc, Deutsche Bank, Management, Capital Management, NRG, Svea, Thomson Locations: Brussels, Belgium, U.S, Danish, Novo, United States, Germany, Boston, London

Wegovy is the first-to-market in a new class of highly effective weight-loss drugs. The self-injection drug has transformed the fortunes of Novo, whose shares have surged about 165% since Wegovy's U.S. launch two years ago. The lion's share may be claimed by frontrunners Novo and its U.S. rival Eli Lilly and Co (LLY.N). Last month, Novo launched Wegovy in Germany, its first big European market. Reporting by Maggie Fick and Jacob Gronholt-Pedersen Editing by Josephine Mason and Mark PotterOur Standards: The Thomson Reuters Trust Principles.

Persons: Novo Nordisk Lars Fruergaard Jorgensen, LUDOVIC MARIN, Lars Fruergaard Jorgensen's, Jorgensen, Eli Lilly, Wegovy, Novo, Maggie Fick, Jacob Gronholt, Pedersen, Josephine Mason, Mark Potter Organizations: Novo Nordisk, Chateau, BMI, Reuters, frontrunners Novo, Pfizer, Thomson Locations: Versailles, Paris, COPENHAGEN, Europe, Danish, United States, Denmark, Norway, Brussels, Wegovy, Germany

☆ Novo Nordisk CEO 'confident' Catalent will resolve Wegovy output problems
▼ + stars: | 2023-08-25 | by ( Maggie Fick | ) www.reuters.com time to read: +2 min

[1/3] A general view of the drug product manufacturing laboratory in biologics and sterile injectables, Catalent, in Brussels, Belgium June 27, 2023. REUTERS/Yves Herman/File Photo Acquire Licensing RightsAug 25 (Reuters) - Novo Nordisk Chief Executive Lars Fruergaard Jorgensen said on Friday he was confident Catalent (CTLT.N) would resolves its problems making Novo's hugely-popular weight-loss drug Wegovy as the company scrambles to boost output to meet soaring demand. "I am confident in that," Jorgensen said at a Reuters Newsmaker event, when asked about the issues Catalent has had. Novo hopes to have a third external facility filling and finishing the injection pens by 2024, Jorgensen said. Even so, it will be "quite some years" before the company can satisfy the whole market for Wegovy, Jorgensen said.

Persons: Yves Herman, Lars Fruergaard Jorgensen, Jorgensen, Catalent, Novo, Maggie Fick, Josephine Mason, Mark Potter Organizations: REUTERS, Novo Nordisk, Reuters, Wegovy, Thomson Locations: Brussels, Belgium, Danish

☆ Novo hires Thermo Fisher as second manufacturer for Wegovy weight-loss drug - source
▼ + stars: | 2023-08-23 | by ( Maggie Fick | ) www.reuters.com time to read: +2 min

A selection of injector pens for the Wegovy weight loss drug are shown in this photo illustration in Chicago, Illinois, U.S., March 31, 2023. REUTERS/Jim Vondruska/Illustration/File Photo Acquire Licensing RightsLONDON, Aug 23 (Reuters) - Novo Nordisk (NOVOb.CO) has hired Thermo Fisher (TMO.N) as its second contract manufacturer for its hugely popular weight-loss drug Wegovy, a source familiar with the matter told Reuters. Thermo is doing the filling of the Wegovy injection pens at its factory in Greenville, North Carolina, the source said, declining to be named because the information is confidential. Novo Chief Financial Officer Karsten Munk Knudsen told Reuters in May the company had signed up a second contract manufacturer in the United States, but the identity of the company has not previously been reported. Wegovy launched in the United States in June 2021, the first-to-market in a new class of highly effective weight-loss drugs.

Persons: Jim Vondruska, Karsten Munk Knudsen, Wegovy, Knudsen, Catalent's, Maggie Fick, Josephine Mason, Mark Potter Organizations: REUTERS, Novo Nordisk, Reuters, Novo, Thomson Locations: Chicago , Illinois, U.S, Greenville , North Carolina, United States, Danish, Brussels, Belgium

☆ Novo hires Thermo Fisher as second manufacturer for Wegovy weight-loss drug -source
▼ + stars: | 2023-08-23 | by ( Maggie Fick | ) www.reuters.com time to read: +2 min

☆ Catalent, facing pressure from Elliott, had other activists in stock
▼ + stars: | 2023-08-14 | by ( Svea Herbst-Bayliss | ) www.reuters.com time to read: +2 min

A general view of the drug product manufacturing laboratory in biologics and sterile injectables, Catalent, in Brussels, Belgium June 27, 2023. Keith Meister's Corvex Management and Scott Ferguson's Sachem Head Capital Management each disclosed buying Catalent stock in the second quarter and owning it on June 30. Corvex initiated a new position in Catalent, buying 5.7 million shares during the second quarter, while Sachem Head purchased 662,000 shares during the quarter, also a new position for the fund. While Elliott is among the world's most prominent and busiest activist investors, both Corvex and Sachem Head have in the past targeted other companies and successfully lobbied for board seats. Representatives for Corvex and Sachem Head declined to comment beyond the filings.

Persons: Yves Herman, Keith Meister's, Scott Ferguson's, Corvex, Elliott, Catalent, Svea Herbst, Bayliss, Sonali Paul Organizations: REUTERS, Elliott Investment Management, Management, Capital Management, Sachem, Corvex, AstraZeneca, Johnson, Moderna, Svea, Thomson Locations: Brussels, Belgium, Catalent, Europe, United States

☆ Insight: Wegovy weight-loss injection factory plagued by sterile-safety failures
▼ + stars: | 2023-07-27 | by ( Maggie Fick | ) www.reuters.com time to read: +10 min

Microbial contamination of drugs injected into the body, rather than swallowed, can be deadly, the people said - although the FDA inspectors didn't report any signs of this sort of contamination at the Brussels factory. In both visits, the FDA inspectors found Catalent staff had repeatedly failed to investigate why equipment was malfunctioning. BLINDSIDED BY BOOMING DEMANDWithin months of launching Wegovy, Novo Nordisk was overwhelmed by demand in America, and told shareholders that its initial supply would not keep pace. From December that year and throughout 2022, Novo repeatedly pushed out the timeline for when the supply constraints would end. In late December 2022, Novo announced all five dose strengths were available again in the United States.

Persons: Wegovy, Catalent, Eli Lilly, LLY.N, Susan Bain, Karsten Munk Knudsen, Ambre James, Brown, James, Knudsen didn't, Steven Lynn, Lynn, David Talmage, didn't, Novo, Maggie Fick, Vincent Flasseur, Michele Gershberg Organizations: U.S . Food, Drug Administration, Reuters, FDA, Novo Nordisk, University of Southern, Novo executives, Novo, U.S, Manufacturing, Parenteral Drug Association, Thomson Locations: U.S, Brussels, Danish, University of Southern California, Wegovy, Novo, America, United States

The company reported a larger-than-expected quarterly loss and cut its annual revenue forecast for the second time, but strength in its biologics unit drove quarterly sales past tempered Wall Street estimates. Catalent's "results cleared an admittedly low bar", Stephens analyst Jacob Johnson said. "After a number of shoes dropping and a lot of noise recently, today was a good first or second step." Catalent reported a third-quarter loss of 9 cents per share, compared with Wall Street estimates for a loss of 3 cents, according to IBES data from Refinitiv. The company will also amend its 2022 results filing with a $26 million deduction caused by a revenue recognition error at its Bloomington plant.

Persons: Stephens, Jacob Johnson, Alessandro Maselli, Maselli, Catalent, Bhanvi Satija, Sriparna Roy, Devika Organizations: Novo Nordisk's, Thomson Locations: Maryland, Brussels, Indiana, Bloomington, Bengaluru

Catalent, one of the top contract manufacturers for pharmaceutical companies, said a drop in revenue from COVID vaccine manufacturing had coincided with higher-than-expected costs and production challenges at its facilities in Indiana and in Brussels. Adding to woes, its cost-cutting plans have been delayed due to regulatory inspections and subsequent corrective actions, the company said. Despite Friday's gain in shares, Catalent's stock is down 19% since it first disclosed production challenges at its three major production plants in April. Catalent cut its full-year revenue to a range of $4.25 billion to $4.35 billion, from its prior forecast of $4.63 billion to $4.88 billion. It also slashed its annual adjusted net income forecast to between $187 million and $228 million, from between $567 million and $648 million previously.

☆ Catalent flags problems at its manufacturing plants; CFO departs
▼ + stars: | 2023-04-14 | by ( ) www.reuters.com time to read: +1 min

The company's clients have included COVID-19 vaccine makers such as Moderna Inc (MRNA.O) and Johnson & Johnson (JNJ.N). Catalent said it experienced "productivity issues" at its gene therapy manufacturing site in Harmans, Maryland, and faced similar issues at its drug product and drug substance manufacturing facilities in Bloomington, Indiana and Brussels, Belgium. The issues would impact financial results for the third quarter and Catalent's forecast for the remainder of fiscal 2023, the company said. Catalent named company insider Ricky Hopson as interim CFO and said it had launched the search for a permanent finance chief. The company's shares were trading at $50.77 before the bell.

☆ PwC isn't panicked about this 'economic pessimism' — in fact, one exec thinks it's an opportunity
▼ + stars: | 2023-02-12 | by ( Tim Paradis | Josée Rose | ) www.businessinsider.com time to read: +5 min

"No management team gets paid to languish," Bricker told Insider. For some top execs, the need to look further ahead is an existential one: Nearly 40% of surveyed CEOs told PwC that they didn't think their organization would be economically viable in a decade without transforming. That's because efforts around diversity could help a company's workforce perform better, and sustainability investments can help companies boost revenue and shave costs. "The strategies that I see business leaders really starting to focus on is not viewing sustainability as a luxury good, but as an essential element of business," Bricker said. The idea of sparing workers where possible aligns with what CEOs told PwC in the survey, which gathered responses from some 4,440 business heads in October and November.

☆ Transforming Business poll shows that talent is a driver, and a product, of innovation
▼ + stars: | 2021-04-20 | by ( Julia Hood | ) www.businessinsider.com time to read: +6 min

Talent recruitment was cited as a top priority for innovation investment among companies polled for the Transforming Business series. Business decision-makers polled by Insider report that talent is a top investment priority, and also that a major benefit of digital transformation is recruiting top talent. Culture of innovationTo drive transformation, business leaders have to source and keep the right talent, and to create a culture of innovation. "Whether businesses recover will be dependent on their talent and that talent's ability to navigate uncertainty and drive innovation needed to rise beyond incremental challenges." This SurveyMonkey Audience poll targeted individuals who work in a management capacity at their company according to the Audience panel.

Search resuls for: "talent's"

24 mentions found